



March 7, 2017

✓ **BSE Limited,**  
Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

**The National Stock Exchange of India Ltd.,**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI**  
**(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards launch of generic Paxil CR® (Paroxetine) Extended Release Tablets USP, 12.5 mg, 25 mg and 37.5 mg, for which the Company received USFDA approval. It is the AB rated generic equivalent of Apotex Technologies, Inc's Paxil CR® Tablets, 12.5 mg, 25 mg and 37.5 mg which are indicated for the treatment of major depressive disorder, panic disorder, social anxiety disorder and premenstrual dysphoric disorder.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

Yours faithfully,  
For **LUPIN LIMITED**

  
For **R. V. SATAM**  
**COMPANY SECRETARY**

Encl.: a.a.

## Lupin launches Generic Paxil CR® tablets in the US

**Mumbai, Baltimore, March 07, 2017:** Pharma Major Lupin Limited (Lupin) announced today the launch of generic Paxil CR® (Paroxetine) Extended Release Tablets USP, 12.5 mg, 25 mg and 37.5 mg having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin's Paroxetine Extended Release Tablets USP, 12.5 mg, 25 mg and 37.5 mg are the AB rated generic equivalents of Apotex Technologies, Inc's Paxil CR® Tablets, 12.5 mg, 25 mg and 37.5 mg. It is indicated for the treatment of major depressive disorder, panic disorder, social anxiety disorder and premenstrual dysphoric disorder.

Paxil CR® Tablets had US sales of USD 126.4 million (IMS MAT December 2016).

### About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 5<sup>th</sup> and the 6<sup>th</sup> largest generics pharmaceutical company by market capitalization (December 31<sup>st</sup>, 2016, Bloomberg) and sales globally (September 30<sup>th</sup>, 2016, Bloomberg). The Company is the 5<sup>th</sup> largest pharmaceutical player in the US by prescriptions (4.68% market share – IMS Health, National Prescription Audit, March 2016); the 2<sup>nd</sup> largest Indian pharmaceutical company by revenues; the 6<sup>th</sup> largest generic pharmaceutical player in Japan and the 4<sup>th</sup> largest generic pharmaceutical company in South Africa (IMS Health, March 2016).

For the financial year ended 31<sup>st</sup> March, 2016, Lupin's Consolidated sales and Net profit stood at Rs. 136,539 million (USD 2.09 billion) and Rs. 22,607 million (USD 345 million) respectively. Please visit <http://www.lupin.com> for more information. You could also follow us on Twitter - [www.twitter.com/lupinlimited](http://www.twitter.com/lupinlimited)

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3<sup>rd</sup> Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

### For further information or queries please contact –

Arvind Bothra  
Head – Investor Relations and M&A  
Ph: +91-22-66402137  
Email: [arvindbothra@lupin.com](mailto:arvindbothra@lupin.com)

#### *\*Safe Harbor Statement*

*Paxil CR® is the registered trademark of GlaxoSmithKline*